Former Ariad Exec Santillana to Join Merrimack Pharmaceuticals

Xconomy Boston — 

Sergio Santillana will become the next chief medical officer of Merrimack Pharmaceuticals (NASDAQ: MACK). Cambridge, MA-based Merrimack said that Santillana will start on June 12. Santillana most recently served as chief medical officer of Ariad Pharmaceuticals, a Cambridge company that was acquired by Japan-based Takeda Pharmaceutical earlier this year. His experience also includes posts at Takeda, GlaxoSmithKline (NYSE: GSK), and Eli Lilly (NYSE: LLY).